Cipla Limited

NSEI:CIPLA Aktierapport

Börsvärde: ₹1.1t

Cipla Framtida tillväxt

Future kriterier kontrolleras 1/6

Cipla förväntas öka intäkter och intäkter med 7.7% respektive 9% per år. EPS förväntas tillväxt med 7.3% per år. Avkastningen på eget kapital förväntas bli 12.8% om 3 år.

Viktig information

7.7%

Tillväxttakt i vinsten

7.26%

Tillväxttakt för EPS

Pharmaceuticals vinsttillväxt17.2%
Intäkternas tillväxttakt9.0%
Framtida avkastning på eget kapital12.83%
Bevakning av analytiker

Good

Senast uppdaterad27 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 16
Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook

Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.

CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook

Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).

CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook

Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).

CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook

Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).

CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook

Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).

CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations

Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).

CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential

Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).

Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next

The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet

CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential

Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?

Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report

Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares

Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly

Emerging Markets And Chronic Therapies Will Open New Horizons

With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.

Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors

Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors

Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly

Jun 03
Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly

Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

May 16
Earnings Beat: Cipla Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
User avatar

Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions

Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.

Prognoser för vinst- och omsättningstillväxt

NSEI:CIPLA - Analytikernas framtida uppskattningar och tidigare finansiella data (INR Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
3/31/2028340,42852,31136,646N/A33
3/31/2027308,80844,76430,194N/A35
3/31/2026283,22641,37531,609N/A34
12/31/2025279,67245,464N/AN/AN/A
9/30/2025279,65854,41127,54442,949N/A
6/30/2025274,79653,925N/AN/AN/A
3/31/2025272,67452,72534,65350,050N/A
12/31/2024267,20149,897N/AN/AN/A
9/30/2024262,64244,75129,52045,008N/A
6/30/2024258,92243,035N/AN/AN/A
3/31/2024255,36741,21627,84641,339N/A
12/31/2023251,16337,082N/AN/AN/A
9/30/2023243,40734,53225,98837,924N/A
6/30/2023235,10831,112N/AN/AN/A
3/31/2023225,59328,01920,73632,377N/A
12/31/2022222,18726,383N/AN/AN/A
9/30/2022218,87425,66020,12029,160N/A
6/30/2022216,10524,884N/AN/AN/A
3/31/2022217,07825,16826,28533,259N/A
12/31/2021210,71825,681N/AN/AN/A
9/30/2021207,61625,87628,36237,113N/A
6/30/2021202,80125,417N/AN/AN/A
3/31/2021191,20524,04929,41837,552N/A
12/31/2020188,77922,374N/AN/AN/A
9/30/2020180,80218,40323,62731,968N/A
6/30/2020174,37716,462N/AN/AN/A
3/31/2020170,80515,46520,68430,685N/A
12/31/2019171,20616,678N/AN/AN/A
9/30/2019167,57216,489N/A25,720N/A
6/30/2019163,73315,546N/AN/AN/A
3/31/2019163,23215,277N/A16,911N/A
12/31/2018155,22413,391N/AN/AN/A
9/30/2018154,28714,074N/AN/AN/A
6/30/2018154,99214,530N/AN/AN/A
3/31/2018151,05314,105N/A14,628N/A
12/31/2017147,61811,701N/AN/AN/A
9/30/2017144,95111,444N/AN/AN/A
6/30/2017141,63710,762N/AN/AN/A
3/31/2017143,34010,064N/A23,818N/A
12/31/2016142,50911,213N/AN/AN/A
9/30/2016137,54710,071N/AN/AN/A
6/30/2016134,33512,219N/AN/AN/A
3/31/2016135,48013,600N/A17,408N/A
12/31/2015135,04416,847N/AN/AN/A
9/30/2015131,63316,694N/AN/AN/A
6/30/2015124,78215,368N/AN/AN/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: CIPLA s prognostiserade vinsttillväxt ( 7.7% per år) är över sparkvoten ( 6.8% ).

Resultat vs marknad: CIPLA s intäkter ( 7.7% per år) förväntas växa långsammare än marknaden för Indian ( 17.5% per år).

Höga tillväxtresultat: CIPLA s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: CIPLA s intäkter ( 9% per år) förväntas växa långsammare än marknaden för Indian ( 11.3% per år).

Hög tillväxtintäkter: CIPLA s intäkter ( 9% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: CIPLA s avkastning på eget kapital förväntas bli låg om 3 år ( 12.8 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/04/30 04:37
Aktiekurs vid dagens slut2026/04/30 00:00
Intäkter2025/12/31
Årlig intjäning2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cipla Limited bevakas av 63 analytiker. 35 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
Nitin BhasinAmbit Capital